Result Update:NOCIL
Axis Direct
We maintain our HOLD rating on the stock.
Broker Research reports: All reports
- This broker has downgraded this stock from it's previous report. (eg. - Buy->Hold)
- Broker has maintained previous recommendation but reduced share price target.
- This broker has upgraded this stock from it's previous report.(eg. - Sell->Hold)
- Broker has maintained previous recommendation but increased share price target.
RESEARCH REPORTS ALERTS
Load latest
Google or static link led you to an intermediate page.
- All Recent
- Upside
- Buy
- Sell
- Recent Upgrades
- Recent Downgrades
- IPO
- Sector Updates
- Most Recent
- Top Upside
Click on any table column to sort reports by date, stock name, broker, price, target, upside or recommendation.
| Summary | Date | Stock | Author | LTP | Target | Price at reco (Change since reco%) |
Upside(%) | Type | Report | Discuss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 30 Oct 2024 | NOCIL |
Axis Direct
|
179.97 | 295.00 | 281.45 (-36.06%) | 63.92 |
Hold
|
||||
| 30 Oct 2024 | Maruti Suzuki |
Axis Direct
|
12641.00 | 12065.00 | 11256.45 (12.30%) | Target met |
Hold
|
||||
| 30 Oct 2024 | Supreme Industries |
Geojit BNP Paribas
|
3803.30 | 4895.00 | 4389.00 (-13.34%) | Target met |
Accumulate
|
||||
| 30 Oct 2024 | Kotak Mahindra Bank |
Geojit BNP Paribas
|
2074.80 | 1902.00 | 1734.60 (19.61%) | Target met |
Hold
|
||||
| 30 Oct 2024 | JSW Energy |
Geojit BNP Paribas
|
504.85 | 733.00 | 674.35 (-25.14%) | Target met |
Hold
|
||||
| 30 Oct 2024 | Jio Financial |
Geojit BNP Paribas
|
273.90 | 347.00 | 319.95 (-14.39%) | Target met |
Hold
|
||||
| 30 Oct 2024 | Sun Pharmaceutical |
KRChoksey
|
1733.40 | 1967.00 | 1852.10 (-6.41%) | 13.48 |
Accumulate
|
US Specialty and domestic business aid strong performance
KRChoksey
Sun Pharma revenue came in-line with our estimates (-1.0%) whereas EBITDA was largely in-line with our estimate (-2.1%) and Adj. PAT missed our estimate due to higher-than-expected finance costs and lower-than-expected other income.
|
|||
| 30 Oct 2024 | Ami Organics |
KRChoksey
|
1186.70 | 1994.00 | 1919.25 (-38.17%) | Target met |
Accumulate
|
Outlook remains strong with robust top-line growth and margin expansion
KRChoksey
Ami Organics’ revenue beat our estimates significantly due to strong growth in Advanced Intermediates. This is reflected in EBITDA and Adj. PAT performance, which beat our estimates primarily due to lower-than-expected employee expenses.
|
|||
| 30 Oct 2024 | Gujarat Fluorochemicals |
KRChoksey
|
3948.20 | 4550.00 | 4250.20 (-7.11%) | 15.24 |
Accumulate
|
Demand recovery and strengthening prices to drive growth across verticals
KRChoksey
GFL Q2FY25 earnings mirrored our projections. Revenue stood at INR 11,880 Mn, up 25.4% YoY (+1.0% QoQ), driven by robust growth in the Fluoropolymers and Fluorochemicals segment partially offset by the weaker Bulk Chemical segment.
|
|||
| 30 Oct 2024 | Krsnaa Diagnostics |
Khambatta Securities
|
638.00 | 970.00 | 950.70 (-32.89%) | Target met |
Hold
|
||||
|
more
loading
|
|||||||||||
* Please note that subscribers can download a maximum of 300 reports a month and 70 reports everyday.